IRIS
D'ALESSANDRO, MIRIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.469
NA - Nord America 3.837
AS - Asia 570
OC - Oceania 14
SA - Sud America 14
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 10.920
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.806
IT - Italia 1.910
IE - Irlanda 1.575
GB - Regno Unito 1.109
SE - Svezia 605
FR - Francia 295
DE - Germania 266
FI - Finlandia 216
RU - Federazione Russa 185
CN - Cina 161
SG - Singapore 151
UA - Ucraina 86
IN - India 84
ES - Italia 83
CZ - Repubblica Ceca 63
VN - Vietnam 44
IR - Iran 28
CA - Canada 27
HK - Hong Kong 19
JP - Giappone 14
PH - Filippine 14
AU - Australia 13
NL - Olanda 11
BE - Belgio 10
CH - Svizzera 8
EU - Europa 6
MK - Macedonia 6
PK - Pakistan 6
PL - Polonia 6
TR - Turchia 6
AT - Austria 5
DK - Danimarca 5
EE - Estonia 5
GE - Georgia 4
HU - Ungheria 4
KR - Corea 4
PT - Portogallo 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
CL - Cile 3
CO - Colombia 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
PE - Perù 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AM - Armenia 2
AZ - Azerbaigian 2
BD - Bangladesh 2
CR - Costa Rica 2
CY - Cipro 2
EG - Egitto 2
ID - Indonesia 2
JO - Giordania 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
QA - Qatar 2
BG - Bulgaria 1
BR - Brasile 1
EC - Ecuador 1
MM - Myanmar 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
Totale 10.920
Salva come PNG Salva come JPEG
Città #
Dublin 1.544
Southend 1.040
Chandler 614
Fairfield 455
Ashburn 378
Lastra a Signa 363
Siena 298
Helsinki 198
Wilmington 188
Woodbridge 181
Princeton 177
Houston 167
Seattle 161
Cambridge 146
Florence 130
New York 126
Ann Arbor 100
Singapore 95
Shanghai 77
Milan 73
Fremont 63
Rome 60
Málaga 59
Moscow 55
San Mateo 54
San Diego 46
Dong Ket 44
Boardman 43
Jacksonville 42
Brno 40
Beijing 33
Munich 32
Washington 32
Dallas 29
London 25
Chicago 23
Agliana 20
Gavirate 20
Los Angeles 20
Olomouc 20
Tarazona 17
Livorno 16
Naples 16
Lappeenranta 15
Hyderabad 13
Zanjan 13
Toronto 12
Aachen 11
Chianciano Terme 11
Dearborn 11
Padova 11
Brussels 10
Comun Nuovo 10
Hong Kong 10
Pasig 10
Redwood City 10
Amsterdam 9
Guangzhou 9
Norwalk 9
Pisa 9
Bangalore 8
Bergamo 8
Catania 8
Grosseto 8
Prato 8
Pune 8
Turin 8
Verona 8
Cagliari 7
Carrara 7
Falkenstein 7
Leawood 7
Salerno 7
San Casciano in Val di Pesa 7
San Francisco 7
Anagni 6
Bari 6
Paris 6
Rubano 6
Treviso 6
Vienna 6
Winnipeg 6
Brescia 5
Chieti 5
Cinisello Balsamo 5
Clifton 5
Delhi 5
Hefei 5
Kilburn 5
Macerata 5
Migliarino 5
Minneapolis 5
Mumbai 5
Newark 5
Rājsamand 5
Tallinn 5
Uzzano 5
Andover 4
Bayreuth 4
Bologna 4
Totale 7.745
Salva come PNG Salva come JPEG
Nome #
Peripheral biomarkers' panel for severe COVID-19 patients 182
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 181
Genetic mechanisms of critical illness in COVID-19 177
null 171
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 162
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 159
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 152
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 150
NK and NKT-like cells in granulomatous and fibrotic lung diseases 149
null 135
Prognostic bioindicators in severe COVID-19 patients 133
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 132
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 132
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 124
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 118
Serial KL-6 measurements in COVID-19 patients 117
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 117
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 115
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 113
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 112
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 111
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 111
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 110
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 109
Pathogen-sugar interactions revealed by universal saturation transfer analysis 108
Serum amyloid A: A potential biomarker of lung disorders 108
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 108
Mapping the human genetic architecture of COVID-19 108
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 107
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 107
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 101
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 100
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 100
Effects of rituximab therapy on B cell differentiation and depletion 99
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 98
A first update on mapping the human genetic architecture of COVID-19 95
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 95
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 95
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 94
Cluster analysis for clinical sarcoidosis' phenotyping 92
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 92
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 91
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 89
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 88
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 87
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 87
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 87
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 86
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 86
Immunologic responses to antifibrotic treatment in IPF patients 86
WES profiling of COVID-19 86
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 84
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 83
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 83
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 82
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 82
An explainable model of host genetic interactions linked to COVID-19 severity 81
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 81
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 81
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 81
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 81
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 79
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 79
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 79
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 78
Inflammatory muscle involvement in systemic vasculitis: A systematic review 78
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 77
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 76
null 75
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 74
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 74
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 73
Clinical phenotyping in sarcoidosis management 73
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 72
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 72
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 71
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 70
Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of Interstitial Lung Disease 68
A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist 67
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 67
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 66
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 65
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 63
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 62
The Role of Galectins in Chronic Lung Allograft Dysfunction 62
Serum Amyloid A in lung transplantation 61
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 61
Serial autoantibody detection in interstitial lung diseases: should they be repeated at follow-up? 60
Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy 60
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 60
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 59
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 58
Prognostic role of NK cell percentages in bronchoalveolar lavage from patients with different fibrotic interstitial lung diseases 56
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy 56
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 53
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 52
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 51
High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool? 51
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 51
Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series 51
Totale 9.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020402 0 0 0 28 30 24 37 45 68 56 41 73
2020/20211.997 60 97 98 276 173 215 149 242 207 108 195 177
2021/20222.151 160 232 194 143 105 100 86 109 96 285 227 414
2022/20232.793 179 302 327 276 156 475 308 238 186 141 118 87
2023/20243.341 122 96 329 192 180 700 929 170 50 118 139 316
2024/2025820 633 187 0 0 0 0 0 0 0 0 0 0
Totale 11.504